Approval · Notice of Compliance 380 · 2002
PLAVIX: Notice of Compliance 380
Issued April 10, 2002
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 380
- Date
- April 10, 2002
- Company
- Sanofi-Synthelabo Canada Inc.Laval, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New indication: reduction of atherothrombotic events in patients with acute coronary syndromes, unstable angina or non-q-wave myocardial infarction, without st segment elevation
- Therapeutic class
- Platelet aggregation inhibitor
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| PLAVIX | Not yet assigned | — |
Medicinal ingredients
- CLOPIDOGREL BISULFATE 75 MG per TAB